Poseida Therapeutics Growth, Revenue, Number of Employees and Funding

Overview

Location:
Total Funding:$226.5M
Industry:Biotech
Founded:2015
Lead Investor(s):Longitude Capital
Press

City Ranking

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Poseida Therapeutics's estimated revenue is currently $14.4M per year.
  • Poseida Therapeutics received $30.0M in venture funding in April 2018.
  • Poseida Therapeutics's estimated revenue per employee is $144150
  • Poseida Therapeutics's total funding is $226.5M.

Employee Data

  • Poseida Therapeutics has 100 Employees.
  • Poseida Therapeutics grew their employee count by 72% last year.
  • Poseida Therapeutics currently has 19 job openings.

Executive Contacts

NameTitle
Joshua RychakDirector (Nanotechnology)
Julia CoronellaSenior Director
Michelle ReslerSenior Director, Clinical Operations
Devon ShedlockVice President, Preclinical Development
Julian DownSenior Director of Gene Therapy
Joanne McCaigueDirector, Clinical Data Management
Glenn DouradoVice President, Business Development
Jennifer CollinsVice President, Quality Operations
Johanna MyletVice President Finance
Danielle CampbellDirector, Human Resources

What Is Poseida Therapeutics?

Poseida Therapeutics is translating best-in-class gene engineering technologies into lifesaving cell therapies. The company is developing CAR T-cell immunotherapies for multiple myeloma, prostate and other cancer types, as well as gene therapies for orphan diseases. P-BCMA-101 is Poseida's lead CAR-T therapy currently in Phase 1 clinical development for the treatment of multiple myeloma. Poseida has assembled a suite of industry-leading gene engineering technologies, including the piggyBac DNA Modification System, TAL-CLOVER and Cas-CLOVER site-specific nucleases, and Footprint-Free Gene Editing (FFGE). For more information, visit www.poseida.com.

keywords:Automotive,Biotechnology,Healthcare,Pharmaceuticals

100

Number of Employees

$14.4M

Revenue (est)

19

Current Jobs

72%

Employee Growth %

$226.5M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Similar Companies

NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
DiaCarta
$6.2M4310%$53M
Mission Bio
$10.7M7445%
Rigel Pharmaceu...
$42M2904%
ProTrials Resea...
$26.4M1823%
Trace Genomics
$5.9M4137%
Advanced Cell D...
$25.7M1788%
CellMax Life
$5.7M4011%$9M
Vaxart
$4.2M33-15%$58.6M
Full Spectrum A...
$6M425%
Calysta
$7.1M49-2%

Poseida Therapeutics News

09/03/2019 - Biotech IPO and M&A predictions from Jefferies analyst ...

More about Poseida Therapeutics: The San Diego-based biopharmaceutical company is developing CAR-T treatments, which harness the ...

04/22/2019 - Poseida Therapeutics Raises $142 Million in Series C Financing

SAN DIEGO, April 22, 2019 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging ...

09/03/2019 - Top 10 Companies Leveraging Gene Editing in 2019

Editas and Intellia, like CRISPR Therapeutics, reached 12-month lows .... Poseida Therapeutics, $226.5 million, Novartis Pharma AG invested ...

Poseida Therapeutics Funding

DateAmountRoundLead InvestorsReference
2015-12-17$30.0MAMalin Corporation plcArticle
2015-12-29$23.0MUndisclosedArticle
2018-04-05$30.0MBLongitude CapitalArticle

Poseida Therapeutics Executive Hires

DateNameTitleReference
2017-01-04Debra GessnerVP Regulatory AffairsArticle
2018-02-06Martin GiedlinVice President, Technical OperationsArticle
2018-03-01Mark Gergenchief business officer and chief financial officer.Article
2018-10-10Marcy GrahamVice President, Corporate AffairsArticle